Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 826

1.

Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group.

Eichenauer DA, Plütschow A, Fuchs M, Sasse S, Baues C, Böll B, von Tresckow B, Diehl V, Borchmann P, Engert A.

J Clin Oncol. 2019 Oct 18:JCO1900986. doi: 10.1200/JCO.19.00986. [Epub ahead of print]

PMID:
31626571
2.

Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.

Fuchs M, Goergen H, Kobe C, Kuhnert G, Lohri A, Greil R, Sasse S, Topp MS, Schäfer E, Hertenstein B, Soekler M, Vogelhuber M, Zijlstra JM, Keller UB, Krause SW, Wilhelm M, Maschmeyer G, Thiemer J, Dührsen U, Meissner J, Viardot A, Eich H, Baues C, Diehl V, Rosenwald A, von Tresckow B, Dietlein M, Borchmann P, Engert A.

J Clin Oncol. 2019 Sep 10:JCO1900964. doi: 10.1200/JCO.19.00964. [Epub ahead of print]

PMID:
31498753
3.

Circular synthesized CRISPR/Cas gRNAs for functional interrogations in the coding and noncoding genome.

Wegner M, Diehl V, Bittl V, de Bruyn R, Wiechmann S, Matthess Y, Hebel M, Hayes MG, Schaubeck S, Benner C, Heinz S, Bremm A, Dikic I, Ernst A, Kaulich M.

Elife. 2019 Mar 6;8. pii: e42549. doi: 10.7554/eLife.42549.

4.

Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.

von Tresckow B, Kreissl S, Goergen H, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group.

Lancet Haematol. 2018 Oct;5(10):e462-e473. doi: 10.1016/S2352-3026(18)30140-6.

PMID:
30290903
5.

Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.

Eichenauer DA, Plütschow A, Schröder L, Fuchs M, Böll B, von Tresckow B, Diehl V, Borchmann P, Engert A.

Blood. 2018 Oct 4;132(14):1519-1525. doi: 10.1182/blood-2018-02-836437. Epub 2018 Jul 31.

PMID:
30064977
6.

Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group.

Eichenauer DA, Plütschow A, Kreissl S, Sökler M, Hellmuth JC, Meissner J, Mathas S, Topp MS, Behringer K, Klapper W, Kuhnert G, Dietlein M, Kobe C, Fuchs M, Diehl V, Engert A, Borchmann P.

Lancet Oncol. 2017 Dec;18(12):1680-1687. doi: 10.1016/S1470-2045(17)30696-4. Epub 2017 Nov 10.

PMID:
29133014
7.

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.

Borchmann P, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer DA, Zijlstra JM, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck HJ, Willenbacher W, Ludwig WD, Pabst T, Topp MS, Hitz F, Bentz M, Keller UB, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Engert A.

Lancet. 2018 Dec 23;390(10114):2790-2802. doi: 10.1016/S0140-6736(17)32134-7. Epub 2017 Oct 20.

PMID:
29061295
8.

The European Cancer Patient's Bill of Rights, update and implementation 2016.

Højgaard L, Löwenberg B, Selby P, Lawler M, Banks I, Law K, Albreht T, Armand JP, Barbacid M, Barzach M, Bergh J, Cameron D, Conte P, de Braud F, de Gramont A, De Lorenzo F, Diehl V, Diler S, Erdem S, Geissler J, Gore-Booth J, Henning G, Horgan D, Jassem J, Johnson P, Kaasa S, Kapitein P, Karjalainen S, Kelly J, Kienesberger A, La Vecchia C, Lacombe D, Lindahl T, Luzzatto L, Malby R, Mastris K, Meunier F, Murphy M, Naredi P, Nurse P, Oliver K, Pearce J, Pelouchov J, Piccart M, Pinedo B, Spurrier-Bernard G, Sullivan R, Tabernero J, Van de Velde C, van Herk B, Vedsted P, Waldmann A, Weller D, Wilking N, Wilson R, Yared W, Zielinski C, Zur Hausen H, Le Chevalier T, Johnston P.

ESMO Open. 2017 Jan 6;1(6):e000127. doi: 10.1136/esmoopen-2016-000127. eCollection 2016. Review.

9.

Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.

Sasse S, Bröckelmann PJ, Goergen H, Plütschow A, Müller H, Kreissl S, Buerkle C, Borchmann S, Fuchs M, Borchmann P, Diehl V, Engert A.

J Clin Oncol. 2017 Jun 20;35(18):1999-2007. doi: 10.1200/JCO.2016.70.9410. Epub 2017 Apr 18.

PMID:
28418763
10.

Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.

Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert A.

Lancet Oncol. 2017 Apr;18(4):454-463. doi: 10.1016/S1470-2045(17)30103-1. Epub 2017 Feb 22.

PMID:
28236583
11.

Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration.

Behringer K, Goergen H, Müller H, Thielen I, Brillant C, Kreissl S, Halbsguth TV, Meissner J, Greil R, Moosmann P, Shonukan O, Rueffer JU, Flechtner HH, Fuchs M, Diehl V, Engert A, Borchmann P.

J Clin Oncol. 2016 Dec 20;34(36):4329-4337. Epub 2016 Oct 31.

PMID:
27998235
12.

Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group.

Kreissl S, Mueller H, Goergen H, Mayer A, Brillant C, Behringer K, Halbsguth TV, Hitz F, Soekler M, Shonukan O, Rueffer JU, Flechtner HH, Fuchs M, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group.

Lancet Oncol. 2016 Oct;17(10):1453-1462. doi: 10.1016/S1470-2045(16)30093-6. Epub 2016 Sep 6.

PMID:
27612583
13.

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials.

Böll B, Goergen H, Behringer K, Bröckelmann PJ, Hitz F, Kerkhoff A, Greil R, von Tresckow B, Eichenauer DA, Bürkle C, Borchmann S, Fuchs M, Diehl V, Engert A, Borchmann P.

Blood. 2016 May 5;127(18):2189-92. doi: 10.1182/blood-2015-11-681064. Epub 2016 Feb 1.

PMID:
26834240
14.

Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group.

Bröckelmann PJ, Goergen H, Fuchs M, Kriz J, Semrau R, Baues C, Kobe C, Behringer K, Eichenauer DA, von Tresckow B, Klimm B, Halbsguth T, Wongso D, Plütschow A, Haverkamp H, Dietlein M, Eich HT, Stein H, Diehl V, Borchmann P, Engert A.

Br J Haematol. 2015 Nov;171(4):547-56. doi: 10.1111/bjh.13646. Epub 2015 Aug 27.

PMID:
26310520
15.

Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group.

Eichenauer DA, Plütschow A, Fuchs M, von Tresckow B, Böll B, Behringer K, Diehl V, Eich HT, Borchmann P, Engert A.

J Clin Oncol. 2015 Sep 10;33(26):2857-62. doi: 10.1200/JCO.2014.60.4363. Epub 2015 Aug 3.

PMID:
26240235
16.

Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials.

Haverkamp H, Böll B, Eichenauer DA, Sasse S, Fuchs M, Borchmann P, Diehl V, Engert A, von Tresckow B.

J Clin Oncol. 2015 Aug 1;33(22):2430-6. doi: 10.1200/JCO.2014.60.4264. Epub 2015 Jun 22.

PMID:
26101245
17.

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.

Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie.

Lancet. 2015 Apr 11;385(9976):1418-27. doi: 10.1016/S0140-6736(14)61469-0. Epub 2014 Dec 22. Erratum in: Lancet. 2015 Apr 11;385(9976):1396.

PMID:
25539730
18.

Improving perfusion quantification in arterial spin labeling for delayed arrival times by using optimized acquisition schemes.

Kramme J, Gregori J, Diehl V, Madai VI, von Samson-Himmelstjerna FC, Lentschig M, Sobesky J, Günther M.

Z Med Phys. 2015 Sep;25(3):221-9. doi: 10.1016/j.zemedi.2014.07.003. Epub 2014 Aug 11.

PMID:
25125192
19.

Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.

Kobe C, Kuhnert G, Kahraman D, Haverkamp H, Eich HT, Franke M, Persigehl T, Klutmann S, Amthauer H, Bockisch A, Kluge R, Wolf HH, Maintz D, Fuchs M, Borchmann P, Diehl V, Drzezga A, Engert A, Dietlein M.

J Clin Oncol. 2014 Jun 10;32(17):1776-81. doi: 10.1200/JCO.2013.53.2507. Epub 2014 May 5.

PMID:
24799482
20.

Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives.

Eichenauer DA, Böll B, Diehl V.

Expert Opin Pharmacother. 2014 Jun;15(8):1139-51. doi: 10.1517/14656566.2014.909411. Epub 2014 Apr 21. Review.

PMID:
24749840
21.

An update on emerging drugs for Hodgkin lymphoma.

von Tresckow B, Diehl V.

Expert Opin Emerg Drugs. 2014 Jun;19(2):215-24. doi: 10.1517/14728214.2014.912277. Epub 2014 Apr 21. Review.

PMID:
24749769
22.

Current status of prognostication in classical Hodgkin lymphoma.

Venkataraman G, Mirza MK, Eichenauer DA, Diehl V.

Br J Haematol. 2014 May;165(3):287-99. doi: 10.1111/bjh.12759. Epub 2014 Feb 4. Review.

PMID:
24494650
23.

A catalyst for change: the European cancer Patient's Bill of Rights.

Lawler M, Le Chevalier T, Murphy MJ Jr, Banks I, Conte P, De Lorenzo F, Meunier F, Pinedo HM, Selby P, Armand JP, Barbacid M, Barzach M, Bergh J, Bode G, Cameron DA, de Braud F, de Gramont A, Diehl V, Diler S, Erdem S, Fitzpatrick JM, Geissler J, Hollywood D, Højgaard L, Horgan D, Jassem J, Johnson PW, Kapitein P, Kelly J, Kloezen S, La Vecchia C, Löwenberg B, Oliver K, Sullivan R, Tabernero J, Van de Velde CJ, Wilking N, Wilson R, Zielinski C, Zur Hausen H, Johnston PG.

Oncologist. 2014 Mar;19(3):217-24. doi: 10.1634/theoncologist.2013-0452. Epub 2014 Feb 3. No abstract available.

24.

Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group.

Eichenauer DA, Thielen I, Haverkamp H, Franklin J, Behringer K, Halbsguth T, Klimm B, Diehl V, Sasse S, Rothe A, Fuchs M, Böll B, von Tresckow B, Borchmann P, Engert A.

Blood. 2014 Mar 13;123(11):1658-64. doi: 10.1182/blood-2013-07-512657. Epub 2014 Jan 29.

PMID:
24478403
25.

Hematology/Oncology Clinics of North America. Hodgkin lymphoma. Preface.

Diehl V, Borchmann P.

Hematol Oncol Clin North Am. 2014 Feb;28(1):ix-x. doi: 10.1016/j.hoc.2013.10.011. No abstract available.

PMID:
24287073
26.

First Hodgkin cell line L428 and the CD30 antigen: their role for diagnostic and treatment of CD30-positive neoplasms.

Stein H, Diehl V.

Hematol Oncol Clin North Am. 2014 Feb;28(1):1-11. doi: 10.1016/j.hoc.2013.10.007. Review.

PMID:
24287063
27.

Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group.

Böll B, Goergen H, Arndt N, Meissner J, Krause SW, Schnell R, von Tresckow B, Eichenauer DA, Sasse S, Fuchs M, Behringer K, Klimm BC, Naumann R, Diehl V, Engert A, Borchmann P.

J Clin Oncol. 2013 Dec 10;31(35):4431-7. doi: 10.1200/JCO.2013.49.8246. Epub 2013 Nov 4.

PMID:
24190119
28.

Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: an analysis of international staging definitions.

Klimm B, Goergen H, Fuchs M, von Tresckow B, Böll B, Meissner J, Glunz A, Diehl V, Eich HT, Engert A, Borchmann P.

Ann Oncol. 2013 Dec;24(12):3070-6. doi: 10.1093/annonc/mdt413. Epub 2013 Oct 22.

PMID:
24148816
29.

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.

Hay AE, Klimm B, Chen BE, Goergen H, Shepherd LE, Fuchs M, Gospodarowicz MK, Borchmann P, Connors JM, Markova J, Crump M, Lohri A, Winter JN, Dörken B, Pearcey RG, Diehl V, Horning SJ, Eich HT, Engert A, Meyer RM; Conducted by the NCIC Clinical Trials Group (Canada) and German Hodgkin Study Group (GHSG).

Ann Oncol. 2013 Dec;24(12):3065-9. doi: 10.1093/annonc/mdt389. Epub 2013 Oct 11.

PMID:
24121121
30.

Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis.

Skoetz N, Trelle S, Rancea M, Haverkamp H, Diehl V, Engert A, Borchmann P.

Lancet Oncol. 2013 Sep;14(10):943-52. doi: 10.1016/S1470-2045(13)70341-3. Epub 2013 Aug 13. Review.

PMID:
23948348
31.

Treatment of advanced-stage hodgkin lymphoma: let us face the facts.

Borchmann P, Kreissl S, Diehl V, Engert A.

J Clin Oncol. 2013 Aug 20;31(24):3045-6. doi: 10.1200/JCO.2013.49.1811. Epub 2013 Jul 8. No abstract available.

PMID:
23835702
32.

Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study group.

Wongso D, Fuchs M, Plütschow A, Klimm B, Sasse S, Hertenstein B, Maschmeyer G, Vieler T, Dührsen U, Lindemann W, Aulitzky W, Diehl V, Borchmann P, Engert A.

J Clin Oncol. 2013 Aug 1;31(22):2819-24. doi: 10.1200/JCO.2012.47.9774. Epub 2013 Jun 24.

PMID:
23796987
33.

ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials.

Böll B, Görgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, Weidmann E, Junghanß C, Greil R, Scherpe A, Schmalz O, Eichenauer DA, von Tresckow B, Rothe A, Diehl V, Engert A, Borchmann P.

J Clin Oncol. 2013 Apr 20;31(12):1522-9. doi: 10.1200/JCO.2012.45.4181. Epub 2013 Mar 18.

PMID:
23509310
34.

Interleukin-10 gene polymorphisms are associated with freedom from treatment failure for patients with Hodgkin lymphoma.

Schoof N, Franklin J, Fürst R, Zander T, von Bonin F, Peyrade F, Trümper L, Diehl V, Engert A, Kube D, Re D.

Oncologist. 2013;18(1):80-9. doi: 10.1634/theoncologist.2012-0291. Epub 2013 Jan 8.

35.

Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials.

Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, Wessels C, Wiehlpütz M, Rosenbrock J, Halbsguth T, Reiners KS, Schober T, Renno JH, von Wolff M, van der Ven K, Kuehr M, Fuchs M, Diehl V, Engert A, Borchmann P.

J Clin Oncol. 2013 Jan 10;31(2):231-9. doi: 10.1200/JCO.2012.44.3721. Epub 2012 Nov 13.

36.

Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma.

Sasse S, Klimm B, Görgen H, Fuchs M, Heyden-Honerkamp A, Lohri A, Koch O, Wilhelm M, Trenn G, Finke J, Müller RP, Diehl V, Eich HT, Borchmann P, Engert A; German Hodgkin Study Group (GHSG).

Ann Oncol. 2012 Nov;23(11):2953-9. doi: 10.1093/annonc/mds110. Epub 2012 Jul 5.

PMID:
22767583
37.

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.

Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl V; German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentöse Tumortherapie.

Lancet. 2012 May 12;379(9828):1791-9. doi: 10.1016/S0140-6736(11)61940-5. Epub 2012 Apr 4. Erratum in: Lancet. 2012 May 12;379(9828):1790.

PMID:
22480758
38.

Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial.

von Tresckow B, Plütschow A, Fuchs M, Klimm B, Markova J, Lohri A, Kral Z, Greil R, Topp MS, Meissner J, Zijlstra JM, Soekler M, Stein H, Eich HT, Mueller RP, Diehl V, Borchmann P, Engert A.

J Clin Oncol. 2012 Mar 20;30(9):907-13. doi: 10.1200/JCO.2011.38.5807. Epub 2012 Jan 23.

PMID:
22271480
39.

Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial.

Behringer K, Thielen I, Mueller H, Goergen H, Eibl AD, Rosenbrock J, Halbsguth T, Eichenauer DA, Fuchs M, Reiners KS, Renno JH, van der Ven K, Kuehr M, von Wolff M, Diehl V, Engert A, Borchmann P.

Ann Oncol. 2012 Jul;23(7):1818-25. doi: 10.1093/annonc/mdr575. Epub 2012 Jan 6.

40.

PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma.

Meadows SA, Vega F, Kashishian A, Johnson D, Diehl V, Miller LL, Younes A, Lannutti BJ.

Blood. 2012 Feb 23;119(8):1897-900. doi: 10.1182/blood-2011-10-386763. Epub 2011 Dec 30.

PMID:
22210877
41.

ABVD versus BEACOPP for Hodgkin's lymphoma.

Borchmann P, Diehl V, Engert A.

N Engl J Med. 2011 Oct 20;365(16):1545-6; author reply 1546. doi: 10.1056/NEJMc1109618. No abstract available.

PMID:
22010928
42.

Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.

Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A.

J Clin Oncol. 2011 Nov 10;29(32):4234-42. doi: 10.1200/JCO.2010.33.9549. Epub 2011 Oct 11.

PMID:
21990399
43.

Chemotherapy: Hodgkin lymphoma--absence of evidence not evidence of absence!

Borchmann P, Engert A, Diehl V.

Nat Rev Clin Oncol. 2011 Oct 4;8(11):636-7. doi: 10.1038/nrclinonc.2011.149. No abstract available.

PMID:
21971592
44.

Lymphocyte-depleted classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin study group.

Klimm B, Franklin J, Stein H, Eichenauer DA, Haverkamp H, Diehl V, Fuchs M, Borchmann P, Engert A.

J Clin Oncol. 2011 Oct 10;29(29):3914-20. doi: 10.1200/JCO.2011.36.4703. Epub 2011 Sep 12.

PMID:
21911729
45.

The unique characteristics and management of patients over 60 years of age with classic Hodgkin lymphoma.

Halbsguth TV, Böll B, Borchmann P, Diehl V.

Curr Hematol Malig Rep. 2011 Sep;6(3):164-71. doi: 10.1007/s11899-011-0089-7. Review.

PMID:
21553348
46.

Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma.

Josting A, Müller H, Borchmann P, Baars JW, Metzner B, Döhner H, Aurer I, Smardova L, Fischer T, Niederwieser D, Schäfer-Eckart K, Schmitz N, Sureda A, Glossmann J, Diehl V, DeJong D, Hansmann ML, Raemaekers J, Engert A.

J Clin Oncol. 2010 Dec 1;28(34):5074-80. doi: 10.1200/JCO.2010.30.5771. Epub 2010 Oct 25.

PMID:
20975066
47.

Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V.

N Engl J Med. 2010 Aug 12;363(7):640-52. doi: 10.1056/NEJMoa1000067.

48.

Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.

Scholz M, Engert A, Franklin J, Josting A, Diehl V, Hasenclever D, Loeffler M; German Hodgkin's Lymphoma Study Group.

Ann Oncol. 2011 Mar;22(3):681-8. doi: 10.1093/annonc/mdq408. Epub 2010 Aug 18.

PMID:
20720088
49.

Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.

Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A.

J Clin Oncol. 2010 Sep 20;28(27):4199-206. doi: 10.1200/JCO.2010.29.8018. Epub 2010 Aug 16.

PMID:
20713848
50.

Emerging drugs for Hodgkin's lymphoma.

Böll B, Borchmann P, Diehl V.

Expert Opin Emerg Drugs. 2010 Dec;15(4):585-95. doi: 10.1517/14728214.2010.505602. Epub 2010 Jul 15. Review.

PMID:
20629601

Supplemental Content

Support Center